S. Moreno

J. Blanco, S. Moreno, B. Alejos, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015.

S. Moreno, J. Berenguer, R. Muga, 2019, Enfermedades infecciosas y microbiologia clinica.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2016, PloS one.

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.

J. Zamora, J. Pérez-Molina, N. Madrid-Elena, 2014, The Journal of antimicrobial chemotherapy.

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

B. Clotet, J. Mallolas, M. Crespo, 2012, The Journal of infection.

Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials.

M. Plana, R. López-Vélez, J. Zamora, 2012, The Journal of antimicrobial chemotherapy.

Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio

A. Royuela, C. Quereda, J. Pérez-Molina, 2014, PloS one.

Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

A. Mocroft, O. Kirk, J. González, 2021, BMC Infectious Diseases.

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy

M. Hernán, J. Arribas, S. Moreno, 2020, Annals of Internal Medicine.

Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

S. Moreno, J. Miró, F. Pulido, 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees.

S. Moreno, C. Ramirez, A. Menasalvas, 2001, Archives of internal medicine.

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.

E. Ribera, S. Moreno, A. Mariño, 2003, AIDS.

Disorders of body fat distribution in HIV-1-infected patients.

E. Negredo, E. Martinez, S. Moreno, 2009, AIDS reviews.

Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy

C. Quereda, S. Moreno, M. Pérez-Elías, 2015, AIDS (London).

Association of Patients’ Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain

F. Vidal, S. Moreno, F. Segura, 2011, Emerging infectious diseases.

Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects

M. Leal, M. Muñoz-Fernández, I. Rosado-Sánchez, 2020, Frontiers in Immunology.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Christopher J. Miller, A. Somasunderam, E. Sinclair, 2017, PLoS pathogens.

Higher vitamin D levels in HIV‐infected out‐patients on treatment with boosted protease inhibitor monotherapy

S. Moreno, R. Torres, J. Jusdado, 2013, HIV medicine.

HIV infection and bone disease: a review of the literature

G. Nunnari, S. Moreno, B. Cacopardo, 2015 .

Expression of gut‐homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV‐1‐infected patients?

M. Muñoz-Fernandez, B. Hernández-Novoa, S. Moreno, 2015, HIV medicine.

HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers

B. Walker, C. Tural, Xu G. Yu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Travelling with HIV in the XXI century: case report and narrative review.

R. López-Vélez, C. Crespillo-Andújar, J. Pérez-Molina, 2020, Travel medicine and infectious disease.

Strategies for the cure of HIV infection

S. Moreno, Jesús Rodríguez-Muñoz, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care

J. Blanco, S. Moreno, P. Viciana, 2012, Antiviral therapy.

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients

J. Miro, E. Poveda, V. Soriano, 2011, AIDS.

Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.

G. Nunnari, S. Moreno, B. Cacopardo, 2014, AIDS reviews.

Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

M. Rava, S. Moreno, A. Antela, 2021, PloS one.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.

E. Negredo, J. Miro, J. Gatell, 2019, Enfermedades infecciosas y microbiologia clinica.

Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients

S. Moreno, M. Pérez-Elías, J. Casado, 2016, AIDS.

Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen

B. Clotet, J. Martinez-Picado, L. Ruiz, 2006, AIDS.

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations

C. Tural, J. Miro, V. Soriano, 2004, Journal of viral hepatitis.

[The cost of treating human immunodeficiency virus infection: Can reasonably be optimized?].

S. Moreno, 2016, Enfermedades infecciosas y microbiologia clinica.

Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain

J. Lazarus, A. Alvaro-Meca, S. Moreno, 2021, Open forum infectious diseases.

Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017

J. del Romero, S. Moreno, M. Riera, 2018, PloS one.

Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

A. Muriel, M. López-Huertas, S. Moreno, 2022, Frontiers in Immunology.

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure

Á. Holguín, E. López-Collazo, J. del Romero, 2020, Medicine.

Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch?

J. Routy, S. Moreno, P. Corbeau, 2019, HIV medicine.

The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences

A. Mocroft, J. Lazarus, J. Lundgren, 2021, AIDS.

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

S. Moreno, M. Pérez-Elías, A. Antela, 2006, AIDS.

Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.

J. Zamora, J. Navarro, M. Crespo, 2017, Enfermedades infecciosas y microbiologia clinica.

Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.

D. Podzamczer, J. Arribas, A. Rivero, 2016, AIDS research and human retroviruses.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

M. Kozal, P. Cahn, J. Aberg, 2020, The lancet. HIV.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 Variants

Á. Holguín, B. Hernández-Novoa, S. Moreno, 2013 .

Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.

C. Quereda, S. Moreno, M. Pérez-Elías, 2010, AIDS.

Raltegravir‐based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus–infected patients after solid organ transplantation

C. Quereda, Ó. Pastor, S. Moreno, 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/μL diagnosed in a high-income country: a multicentre cohort study.

C. Lumbreras, J. Macías, C. González-Domenech, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

J. Sterne, O. Kirk, C. Tural, 2015, Journal of acquired immune deficiency syndromes.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Christopher J. Miller, T. Chun, A. Somasunderam, 2016, PLoS pathogens.

Focal Monophasic Demyelinating Leukoencephalopathy in Advanced HIV Infection

M. García-Villanueva, A. Ariza, C. Quereda, 2004, European Neurology.

Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.

S. Moreno, J. Casado, A. Moreno, 2015, Antiviral Research.

Definition of advanced age in HIV infection: looking for an age cut-off.

M. Vallejo, J. Blanco, S. Moreno, 2012, AIDS research and human retroviruses.

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

B. Clotet, J. Mallolas, J. Macías, 2012, HIV clinical trials.

Lipid and Apoprotein Profile in HIV-1-Infected Patients After CD4-Guided Treatment Interruption

M. Muñoz-Fernández, J. Arribas, S. Moreno, 2008, Journal of acquired immune deficiency syndromes.

Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US

J. Sterne, M. Bickel, T. Sterling, 2015, Antiviral therapy.

Treatment options for AIDS patients with progressive multifocal leukoencephalopathy.

S. Moreno, F. Dronda, Beatríz Hernández, 2009, Expert opinion on pharmacotherapy.

Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994-1997 versus 1998-2000).

S. Moreno, M. Pérez-Elías, A. Antela, 2002, AIDS.

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

D. Podzamczer, C. Vidal, B. Rodés, 2020, AIDS Research and Therapy.

Durability of First-Line Antiretroviral Regimens in the era of Integrase Inhibitors: A Cohort of HIV-Positive Individuals in Spain, 2014–2015

J. del Romero, S. Moreno, J. Peraire, 2019, Antiviral therapy.

HIV, HPV, and microbiota: partners in crime?

A. Latorre, M. Gosalbes, J. Pérez-Molina, 2017, AIDS.

Comparative eff ectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

J. Sterne, C. Sabin, H. Furrer, 2015 .

HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

A. Alvaro-Meca, S. Moreno, J. Troya, 2018, PloS one.

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals

A. Zlotnik, J. Pérez-Molina, S. Moreno, 2017, Antimicrobial Agents and Chemotherapy.

Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response

M. Esteban, C. Quereda, S. Moreno, 2015, Digestive Diseases and Sciences.

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, The Journal of infection.

Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

M. Hernán, A. Curran, J. Arribas, 2022, AIDS.

Report of a European Working Group on Late Presentation with HIV Infection: Recommendations and Regional Variation

M. Johnson, Y. Yazdanpanah, J. Rockstroh, 2010, Antiviral therapy.

Introduction to Late Presentation for HIV Treatment in Europe

M. Johnson, Y. Yazdanpanah, J. Rockstroh, 2010, Antiviral therapy.

Partial Splenic Embolization for the Treatment of Hypersplenism in Cirrhotic HIV/HCV Patients Prior to Pegylated Interferon and Ribavirin

C. Quereda, S. Moreno, M. Pérez-Elías, 2004, Antiviral therapy.

All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection.

C. Lewden, S. Moreno, F. Segura, 2012, Journal of hepatology.

Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

S. Moreno, J. Casado, P. Vizcarra, 2019, HIV research & clinical practice.

Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients

S. Moreno, J. L. Agud, M. Cervero, 2018, PloS one.

High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin

A. Muriel, C. Quereda, E. Navas, 2004, Antiviral therapy.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients

J. Zamora, M. Muñoz-Fernández, E. Muñoz, 2012, AIDS.

Correlation Between Different Methods to Measure Microbial Translocation and Its Association With Immune Activation in Long-Term Suppressed HIV-1–Infected Individuals

B. Hernández-Novoa, S. Moreno, A. Vallejo, 2013, Journal of acquired immune deficiency syndromes.

The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score

C. Quereda, B. Hernández-Novoa, S. Moreno, 2011, AIDS.

Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.

V. Falcó, J. Ena, S. Moreno, 2006, Journal of acquired immune deficiency syndromes.

The influence of patient beliefs and treatment satisfaction on the discontinuation of current first‐line antiretroviral regimens

S. Moreno, A. Moreno, J. Casado, 2016, HIV medicine.

Effect of the Use of Galectin-9 and Blockade of the TIM-3 Receptor in the Latent Cellular Reservoir of HIV-1

N. Madrid-Elena, S. Moreno, A. Vallejo, 2020, Journal of Virology.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

C. Quereda, S. Moreno, M. Pérez-Elías, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

J. J. de la Cruz, V. Soriano, M. Vogel, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study].

S. Hernandez, J. Arribas, C. Quereda, 2005, Enfermedades infecciosas y microbiologia clinica.

HIV infection and aging.

J. Blanco, S. Ferrando-Martínez, S. Moreno, 2010, AIDS reviews.

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

D. Podzamczer, E. Poveda, J. Arribas, 2021, Clinical Microbiology and Infection.

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

J. Gatell, E. Martinez, J. De La Torre, 2018, Enfermedades infecciosas y microbiologia clinica.

Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

J. Gatell, J. De La Torre, M. Crespo, 2017, Enfermedades infecciosas y microbiologia clinica.

Didanosine Enteric-Coated Capsule

S. Moreno, F. Dronda, Beatríz Hernández, 2012, Drugs.

Effect of food on the antiviral activity of didanosine enteric‐coated capsules: a pilot comparative study *

B. Hernández-Novoa, S. Moreno, A. Antela, 2008, HIV medicine.

A Cohort Study of the Food Effect on Virological Failure and Treatment Discontinuation in Patients on HAART Containing Didanosine Enteric-Coated Capsules (FOODDIe Study)

B. Clotet, S. Moreno, J. Hernández-Quero, 2006, HIV clinical trials.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries

James M Robins, Roger Logan, Jonathan A C Sterne, 2011, Annals of Internal Medicine.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

A. Somasunderam, E. Sinclair, D. Asmuth, 2016, PLoS pathogens.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

Brucellosis in patients infected with the human immunodeficiency virus

D. Podzamczer, J. Miro, A. Rivero, 1998, European Journal of Clinical Microbiology and Infectious Diseases.

Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference

J. Castilla, A. Moreno, C. Quereda, 2002, HIV clinical trials.

Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014.

A. Muriel, S. Moreno, M. Pérez-Elías, 2021, Enfermedades infecciosas y microbiologia clinica.

Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker

S. Moreno, J. Casado, A. Chamorro, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results].

Santiago Pérez-Hoyos, Santiago Moreno, Félix Gutiérrez, 2007, Enfermedades infecciosas y microbiologia clinica.

CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use

J. Zamora, A. Muriel, C. Quereda, 2004, AIDS.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

E. Negredo, J. Miro, E. Martinez, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Once-daily antiretroviral therapy: Spanish Consensus Statement.

D. Podzamczer, J. Mallolas, J. Ena, 2005, The Journal of antimicrobial chemotherapy.

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.

E. Martinez, J. Pérez-Molina, S. Moreno, 2008, The Journal of antimicrobial chemotherapy.

Immunotherapy and therapeutic vaccines in HIV infection.

Felipe García, S. Moreno, P. Domingo, 2005, Enfermedades infecciosas y microbiologia clinica.

Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study

A. Mocroft, J. Lundgren, J. Rockstroh, 2018, Antiviral therapy.

Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.

R. Fernández-Muñoz, C. Quereda, S. Moreno, 2006, Human pathology.

Tuberculosis complicating hepatitis C treatment in HIV-infected patients.

A. Muriel, P. Martín-Dávila, C. Quereda, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

F. Antunes, C. Katlama, A. Lazzarin, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy

B. Clotet, J. Arribas, A. Rivero, 2011, AIDS.

Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016.

Felipe García, J. Losa, J. Olalla, 2017, Enfermedades infecciosas y microbiologia clinica.

Antiretroviral therapy in AIDS patients with tuberculosis.

S. Moreno, F. Dronda, Beatríz Hernández, 2006, AIDS reviews.

Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

K. Hertogs, S. Moreno, A. Antela, 2001, AIDS research and human retroviruses.

Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.

J. Castilla, F. Vidal, S. Moreno, 2006, AIDS research and human retroviruses.

Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.

S. Moreno, M. Pérez-Elías, A. Antela, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients

S. Moreno, J. Casado, A. Moreno, 2014, Osteoporosis International.

Increased prevalence of asymptomatic vertebral fractures in HIV-infected patients over 50 years of age

S. Moreno, J. Casado, W. A. Sifuentes, 2018, Archives of Osteoporosis.

Are toxicities of current nucleosides still a concern?

S. Moreno, M. Vivancos, 2018, The lancet. HIV.

Secondary hyperparathyroidism in HIV‐infected patients: relationship with bone remodeling and response to vitamin D supplementation

S. Moreno, F. Dronda, M. P. Pérez Elías, 2012 .

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

James M Robins, Santiago Pérez-Hoyos, Jonathan A C Sterne, 2010, AIDS.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

J. Navarro, J. Pérez-Molina, A. Rivero, 2015, The Lancet. Infectious diseases.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

B. Clotet, M. Odriozola, J. Olalla, 2017, The Journal of antimicrobial chemotherapy.

HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases

M. Ferrer, C. Barbas, A. Latorre, 2016, Scientific Reports.

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

A. Latorre, M. Leal, M. Gosalbes, 2014, Mucosal Immunology.

Towards an HIV cure: a global scientific strategy

M. Lederman, J. Mullins, A. Telenti, 2012, Nature Reviews Immunology.

Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes.

E. Navas, S. Moreno, A. Antela, 2001, AIDS.

Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.

B. Rodés, S. Moreno, M. Pérez-Elías, 2019, Epigenomics.

Frailty, markers of immune activation and oxidative stress in HIV infected elderly

S. Álvarez, M. Muñoz-Fernández, S. Moreno, 2020, PloS one.

The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults

J. Zamora, M. Muñoz-Fernández, S. Moreno, 2013, AIDS.

Relapsing Visceral Leishmaniasis in HIV-Infected Patients Undergoing Successful Protease Inhibitor Therapy

R. López-Vélez, C. Quereda, S. Moreno, 2001, European Journal of Clinical Microbiology and Infectious Diseases.

Sacral myeloradiculitis complicating genital herpes in a HIV-infected patient

C. Quereda, E. Navas, S. Moreno, 2005, International journal of STD & AIDS.

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.

R. Paredes, E. Poveda, J. Córdoba, 2010, AIDS reviews.

Search for human herpesvirus 6 DNA in cerebrospinal fluid from AIDS patients with progressive multifocal leukoencephalopathy

C. Quereda, S. Moreno, M. Pérez-Elías, 2011, Journal of NeuroVirology.

Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort

M. Leal, F. Vidal, J. Blanco, 2006, PloS one.

The potential role of the HIV-1 immunogen (Remune®) as a therapeutic vaccine in the treatment of HIV infection

J. González-lahoz, S. Moreno, J. Carbone, 2003, Expert review of vaccines.

Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis

P. Martín-Dávila, C. Quereda, E. Navas, 2004, European Journal of Clinical Microbiology and Infectious Diseases.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

B. Walker, C. Tural, M. Lichterfeld, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Highlights from the 22nd International AIDS Conference (AIDS 2018), 22–27 July 2018, Amsterdam, the Netherlands

J. Routy, S. Collins, S. Moreno, 2018, Journal of virus eradication.

Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort.

S. Pérez-Hoyos, S. Moreno, J. Oteo, 2007, Journal of women's health.

Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.

C. Quereda, S. Moreno, M. Pérez-Elías, 2008, AIDS.

Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.

G. Appendino, M. Calzado, E. Muñoz, 2011, Current drug targets.

Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

Coral Barbas, Santiago Moreno, C. Barbas, 2016, AIDS.

The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.

Miguel Ángel Martínez, J. Olalla, A. Aguilera, 2020, The Journal of antimicrobial chemotherapy.

Follow-up losses of people with HIV infection: A weak point in the continuum of care

S. Moreno, M. Vivancos, María J Vivancos, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Fecal microbiota transplantation in HIV: A pilot placebo-controlled study

M. Osman, J. Zamora, M. Gosalbes, 2021, Nature Communications.

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

B. Clotet, J. Schapiro, S. Moreno, 2007, The Journal of antimicrobial chemotherapy.

[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up].

S. Moreno, J. Berenguer, F. Gutiérrez, 2011, Enfermedades infecciosas y microbiologia clinica.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1

Santiago Moreno, M. Martínez-Bonet, E. Muñoz, 2015, Scientific Reports.

Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.

S. Álvarez, M. Martínez-Bonet, M. Muñoz-Fernández, 2015, Antiviral research.

Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?

M. J. Serramía, M. Martínez-Bonet, M. Muñoz-Fernández, 2015, Journal of virus eradication.

[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].

B. Clotet, J. Gatell, J. Arribas, 2010, Enfermedades infecciosas y microbiologia clinica.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

S. Moreno, R. Sánchez-de la Rosa, Luis Herrera, 2008, Clinical therapeutics.

Missing Scheduled Visits in the Outpatient Clinic as a Marker of Short-Term Admissions and Death

A. Muriel, S. Moreno, M. Pérez-Elías, 2012, HIV clinical trials.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

D. Podzamczer, B. Clotet, J. Gatell, 2014, Enfermedades infecciosas y microbiologia clinica.

Past and future of HIV infection. A document based on expert opinion

D. Podzamczer, J. Martinez-Picado, E. Ruiz-Mateos, 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21

M. Leal, Y. Pacheco, C. Quereda, 2020, Journal of clinical medicine.

Bone disease in the setting of HIV infection: update and review of the literature.

G. Nunnari, M. Di Rosa, S. Moreno, 2013, European review for medical and pharmacological sciences.

Outcome of HCV/HIV‐Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

E. Cordero, A. Rimola, J. Torre-Cisneros, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients

J. Blanco, S. Moreno, M. Pérez-Elías, 2016, Antiviral therapy.

Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions

M. Muñoz-Fernandez, J. Arribas, S. Moreno, 2008, BMC infectious diseases.

Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain

B. Clotet, M. Leal, S. Moreno, 2009, HIV clinical trials.

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions

E. Martinez, A. Rivero, S. Moreno, 2016, Open forum infectious diseases.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006.

F. Vidal, J. Pineda, S. Moreno, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

P. Vanhems, O. Kirk, R. Paredes, 2014 .

Cerebrovascular Ischemic Events in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy: Incidence and Risk Factors

J. Masjuán, A. Muriel, C. Quereda, 2009, Cerebrovascular Diseases.

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.

A. Muriel, S. Moreno, M. Vivancos, 2020, The lancet. HIV.

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure

P. Soler-Palacín, Á. Holguín, J. Losa, 2021, The Journal of antimicrobial chemotherapy.

Prevalence and outcomes of pregnancies in women living with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015.

A. Mocroft, M. Battegay, D. Raben, 2021, AIDS.

COVID‐19 in hospitalized HIV‐positive and HIV‐negative patients: A matched study

J. Arribas, J. Blanco, S. Moreno, 2021, HIV medicine.

Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1–HCV-Coinfected Patients Who Either Received Interferon-&agr;/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance

C. Quereda, S. Moreno, M. Pérez-Elías, 2015, Journal of acquired immune deficiency syndromes.

Blood Bacterial Profiles Associated with HIV Infection and Immune Recovery.

F. Servant, M. Ferrer, B. Lelouvier, 2020, The Journal of infectious diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe.

A. Mocroft, J. Lundgren, V. Vullo, 2019, AIDS.

High levels of CD4+ CTLA-4+ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis

S. Moreno, A. Vallejo, F. Dronda, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Sex Differences in People Aging With HIV.

J. Milic, G. Cuomo, C. Mussini, 2020, Journal of acquired immune deficiency syndromes.

Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals

M. Ferrer, Rafael Bargiela, C. Barbas, 2016, EBioMedicine.

Visceral leishmaniasis as an independent cause of high immune activation, T‐cell senescence, and lack of immune recovery in virologically suppressed HIV‐1‐coinfected patients

S. Moreno, A. Vallejo, M. Abad-Fernández, 2015, HIV medicine.

HTLV-2b among HIV type 1-coinfected injecting drug users in Spain.

S. Moreno, A. Vallejo, F. Dronda, 2010, AIDS research and human retroviruses.

Exploiting the Microbiota for the Diagnosis of Anal Precancerous Lesions in Men Who Have Sex With Men.

J. Zamora, M. Gosalbes, B. Monge-Maillo, 2021, The Journal of infectious diseases.

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study

A. Muriel, J. Pérez-Molina, S. Moreno, 2020, Clinical Microbiology and Infection.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations

C. Morrison, P. Vanhems, A. Kamali, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

M. Ferrer, M. Motilva, C. Barbas, 2016, Mucosal Immunology.

Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients

S. Moreno, C. Rodríguez, J. Oteo, 2016, PloS one.

Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1–Infected Patients Treated With Combined Antiretroviral Therapy

E. Siles, F. Vidal, J. Blanco, 2015, Journal of acquired immune deficiency syndromes.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Anne M Johnson, A. Mocroft, O. Kirk, 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.

J. Blanco, S. Moreno, F. Pulido, 2016, The Journal of infection.

“It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

D. Ward, M. Murray, U. Bredeek, 2020, PloS one.

Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota

M. Ferrer, Rafael Bargiela, C. Barbas, 2018, AIDS.

The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.

S. Moreno, J. Casado, A. Moreno, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The signi fi cance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunode fi ciency virus-infected patients

S. Moreno, J. Casado, A. Moreno, 2013 .

Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.

A. Royuela, C. Quereda, E. Navas, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

M. Hernán, J. Arribas, X. García-Albéniz, 2022, Clinical Microbiology and Infection.

[Human immunodeficiency virus infection in Spain: it is time to act].

J. del Romero, S. Moreno, J. Del Amo, 2014, Enfermedades infecciosas y microbiologia clinica.

Is it time to start new HIV prevention strategies in Spain

A. Rivero, S. Moreno, 2017 .

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

M. Gosalbes, A. Moya, J. Vázquez-Castellanos, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment options for AIDS patients with progressive multifocal leukoencephalopathy

S. Moreno, F. Dronda, Beatríz Hernández, 2009, Expert opinion on pharmacotherapy.

Phenotypic testing predicts virological response in successive protease inhibitor-based regimens

R. Lanier, S. Moreno, M. Pérez-Elías, 2000, AIDS.

Differences in Durability of Treatment with Initial PI-Based Regimens

C. Quereda, E. Navas, S. Moreno, 2003, HIV clinical trials.

Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

B. Clotet, J. Schapiro, A. Ornelas, 2012, The Journal of antimicrobial chemotherapy.

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen

K. Hertogs, S. Moreno, M. Pérez-Elías, 2002, AIDS.

Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era

E. Navas, S. Moreno, Í. Corral, 2014, European Journal of Clinical Microbiology & Infectious Diseases.

Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

Xavier Barber, Santiago Moreno, Sergio Padilla, 2017, PloS one.

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis

S. Moreno, M. Pérez-Elías, A. Moreno, 2014, Journal of the International AIDS Society.

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients

J. Mallolas, J. Macías, S. Moreno, 2010, Journal of the International AIDS Society.

Comparison of Antiviral Activity of Regimens Containing Nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue Therapy (The NUCREST Study)

A. Milinkovic, A. Curran, J. Pérez-Molina, 2010, HIV clinical trials.

Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype

M. Guiguet, S. Pérez-Hoyos, M. Dorrucci, 2014, Journal of acquired immune deficiency syndromes.

Frailty and physical function in older HIV-infected adults

S. Moreno, M. Pérez-Elías, A. Moreno, 2017, Age and ageing.

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

J. Alcamí, M. López-Huertas, M. Coiras, 2017, Scientific Reports.

Role of the dental surgeon in the early detection of adults with underlying HIV infection / AIDS

J. Cano, J. Campo, J. del Romero, 2011, Medicina oral, patologia oral y cirugia bucal.

SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.

M. Hernán, S. Moreno, J. Del Amo, 2021, AIDS.

Impact of a structured HIV testing program in a hospital emergency department and a primary care center

A. Muriel, C. Quereda, E. Navas, 2019, PloS one.

Gender-based vulnerability in women who inject drugs in a harm reduction setting

A. Alvaro-Meca, S. Moreno, Jorge Valencia, 2020, PloS one.

Pneumococcal vaccination in adult people living with HIV on suppressive antiretroviral therapy: a case–control study

A. Muriel, C. Quereda, J. Valencia-Martín, 2019, International journal of STD & AIDS.

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients

S. Moreno, M. Pérez-Elías, A. Moreno, 2014, Journal of the International AIDS Society.

Redefining therapeutic success in HIV patients: an expert view

J. Olalla, A. Rivero, S. Moreno, 2021, The Journal of antimicrobial chemotherapy.

Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

A. Muriel, J. Pérez-Molina, S. Moreno, 2020, medRxiv.

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

J. Zamora, M. Muñoz-Fernández, E. Muñoz, 2011, PloS one.

Observational Study to Evaluate Clinical Outcomes After First-Line Efavirenz-or Lopinavir-Ritonavir-Based HAART in Treatment-Naive Patients

C. Quereda, E. Navas, S. Moreno, 2009, Journal of the International Association of Physicians in AIDS Care.

Interruption to treatment with combined lopinavir-ritonavir therapy in HIV positive patients

S. Moreno, A. R. Milla, J. S. Genoves, 2007 .

[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].

B. Clotet, J. Miro, J. Gatell, 2004, Enfermedades infecciosas y microbiologia clinica.

Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort

S. Moreno, P. Arazo, P. Viciana, 2014, HIV medicine.

Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.

E. Navas, S. Moreno, M. Rodríguez-Zapata, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death

C. Sabin, A. Walker, S. Pérez-Hoyos, 2016, Journal of acquired immune deficiency syndromes.

Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.

K. Mayer, S. Deeks, C. Achenbach, 2020, The Journal of antimicrobial chemotherapy.

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

A. Rodgers, S. Moreno, Yan Zhou, 2017, The Journal of antimicrobial chemotherapy.

Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

D. Podzamczer, J. Peña, S. Moreno, 2001, AIDS.

[Aspergillosis. Clinical forms and treatment].

S. Moreno, J. Fortún, G. Fresco, 2012, Enfermedades infecciosas y microbiologia clinica.

Development and Validation of an HIV Risk Exposure and Indicator Conditions Questionnaire to Support Targeted HIV Screening

A. Muriel, C. Quereda, S. Moreno, 2016, Medicine.

Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2018, Journal of acquired immune deficiency syndromes.

Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation

S. Moreno, S. Serrano-Villar, 2016, EBioMedicine.

Association of CD4:CD8 With Cause-Specific Mortality in Patients on Long-Term ART

J. Sterne, P. Reiss, M. Gill, 2015 .

The CD4:CD8 ratio is associated with markers of age‐associated disease in virally suppressed HIV‐infected patients with immunological recovery

S. Moreno, M. Fuentes-Ferrer, V. Estrada, 2014, HIV medicine.

Increase of Transmitted Drug Resistance among HIV-Infected Sub-Saharan Africans Residing in Spain in Contrast to the Native Population

Á. Holguín, M. de Mulder, J. Pérez-Molina, 2011, PloS one.

Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment.

M. Leal, I. Herrero-Fernández, I. Rosado-Sánchez, 2018, The Journal of infection.

All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010

S. Moreno, R. Palacios, J. Berenguer, 2013, BMC Infectious Diseases.

Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART.

M. Leal, Y. Pacheco, F. Vidal, 2009, Current HIV research.

Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.

M. Hernán, H. Günthard, C. Sabin, 2019, Journal of acquired immune deficiency syndromes.

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

R. Paredes, D. Podzamczer, M. Noguera-Julián, 2020, The Journal of antimicrobial chemotherapy.

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.

E. Poveda, J. Blanco, J. Olalla, 2019, The Journal of antimicrobial chemotherapy.

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

Á. Holguín, B. Hernández-Novoa, S. Moreno, 2013, HIV clinical trials.

Prevalence of undiagnosed HIV infection in the general population having blood tests within primary care in Madrid, Spain

S. Moreno, B. Ramos, J. Sanz, 2012, Sexually Transmitted Infections.

Imputation of the Date of HIV Seroconversion in a Cohort of Seroprevalent Subjects: Implications for Analysis of Late HIV Diagnosis

R. Geskus, S. Pérez-Hoyos, J. del Romero, 2011, AIDS research and treatment.

Phenotype or Virtual Phenotype for Choosing Antiretroviral Therapy after Failure: A Prospective, Randomized Study

Ana Moreno, José Sanz, Víctor Abraira, 2002, Antiviral therapy.

Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain.

P. L. López, Miguel Ángel Martínez, D. Podzamczer, 2019, The Journal of antimicrobial chemotherapy.

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies

J. Sterne, A. Phillips, F. Dabis, 2013, AIDS.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717

J. Gatell, A. De Luca, J. Zamora, 2018, The Journal of antimicrobial chemotherapy.

[The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].

J. Caylà, A. Rivero, S. Moreno, 2013, Enfermedades infecciosas y microbiologia clinica.

Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey

J. Zamora, J. Pérez-Molina, S. Moreno, 2020, EClinicalMedicine.

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study

J. Robins, M. Hernán, S. Hernández-Díaz, 2016, Journal of acquired immune deficiency syndromes.

HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.

A. Muriel, P. Martín-Dávila, C. Quereda, 2005, Journal of hepatology.

Early diagnosis.

S. Moreno, J. Berenguer, M. J. Fuster-RuizdeApodaca, 2018, Enfermedades infecciosas y microbiologia clinica.

The future of antiretroviral therapy: challenges and needs.

E. Ribera, J. Arribas, A. Rivero, 2010, The Journal of antimicrobial chemotherapy.

Liver transplantation in HIV‐infected recipients

P. Martín-Dávila, C. Quereda, Miguel García, 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy

M. Hernán, J. Arribas, S. Moreno, 2021, Annals of Internal Medicine.

Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.

S. Moreno, M. Pérez-Elías, J. Casado, 2015, The Journal of antimicrobial chemotherapy.

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus‐coinfected patients receiving an etravirine‐containing antiretroviral regimen: influence of liver fibrosis

C. Quereda, S. Moreno, A. Moreno, 2016, HIV medicine.

Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.

C. Quereda, S. Moreno, M. Pérez-Elías, 2012, Journal of acquired immune deficiency syndromes.

New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144

J. Blanco, M. Leal, I. Rosado-Sánchez, 2020, Scientific Reports.

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

J. Sánchez-Payá, S. Moreno, J. Portilla, 2006, European Journal of Clinical Microbiology and Infectious Diseases.

Interplay between gut microbiota metabolism and inflammation in HIV infection

M. Ferrer, C. Barbas, A. Latorre, 2018, The ISME Journal.

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults.

F. García, S. Moreno, C. Rodríguez, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

R. Paredes, E. Poveda, J. Córdoba, 2012, AIDS reviews.

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

S. Moreno, R. Muga, V. Asensi, 2019, PLoS ONE.

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

D. Podzamczer, B. Clotet, J. Gatell, 2015, Enfermedades Infecciosas y Microbiologia Clinica.

Clinicoepidemiological characteristics of HIV-infected immigrants attended at a tropical medicine referral unit.

R. López-Vélez, J. Pérez-Molina, M. Navarro, 2009, Journal of travel medicine.

Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

E. Ribera, M. Rava, S. Moreno, 2021, AIDS.

Validation of a Specific Questionnaire on Psychological and Social Repercussions of the Lipodystrophy Syndrome in HIV-infected Patients

S. Moreno, A. Antela, J. Casado, 2006, Quality of Life Research.

Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co‐infection

C. Tural, J. del Romero, J. Pineda, 2009, Journal of viral hepatitis.

Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM

J. Pérez-Molina, J. del Romero, J. Blanco, 2017, PloS one.

Delayed GALT reconstitution in duodenum compared to rectum in hiv-infected patients initiating antiretroviral therapy.

T. Chun, A. Somasunderam, E. Sinclair, 2019, AIDS.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2017, PloS one.

The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment

N. Pantazis, A. Kelleher, D. Costagliola, 2016, AIDS.

Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, AIDS.

The effect on survival of a multidimensional intervention project (SEAD) in HIV/AIDS patients with follow‐up and adherence (FUP/ADH) barriers

A. Muriel, C. Quereda, E. Navas, 2012 .

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir

V. Abraira, S. Moreno, M. Pérez-Elías, 2005, AIDS.

Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy.

M. Leal, M. Salavert, F. Vidal, 2008, Current HIV research.

The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review

J. Aberg, S. Moreno, A. Clark, 2023, Antiviral therapy.

Recommendations for the early diagnosis of suspected human immunodeficiency virus infection in the emergency department and the referral of patients for follow-up: a consensus statement of the Spanish Society of Emergency Medicine (SEMES).

Ò. Miró, G. Burillo-Putze, A. Curran, 2020, Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias.

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

S. Moreno, M. Pérez-Elías, J. Casado, 2014, Journal of NeuroVirology.

Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients

F. Liaño, S. Moreno, M. Pérez-Elías, 2016, Journal of acquired immune deficiency syndromes.

Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.

I. Oyagüez, M. Casado, S. Moreno, 2010, Clinical therapeutics.

“Real Life” Safety and Efficacy of IFN/RBV-Free, Full-Dose SOF-Based Therapy in Kidney Transplanted Patients

C. Quereda, F. Liaño, S. Moreno, 2016 .

“Real Life” Data on Daas Use among HCV-Patients with Moderate to Severe Chronic Kidney Disease not on Hemodialysis

C. Quereda, S. Moreno, M. Pérez-Elías, 2016 .

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

C. Quereda, S. Moreno, M. Pérez-Elías, 2004, AIDS.

Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients

C. Quereda, S. Moreno, M. Pérez-Elías, 2008, Journal of acquired immune deficiency syndromes.

Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia

S. Moreno, J. Casado, 2016 .

Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status.

M. Leal, M. Leal, F. Vidal, 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

M. Hernán, J. Sterne, C. Sabin, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Regional differences in self-reported HIV care and management in the EuroSIDA study

A. Mocroft, O. Kirk, J. Lazarus, 2014, Journal of the International AIDS Society.

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

Santiago Moreno, M. Muñoz-Fernández, M. Bellido, 2010, Current HIV research.

Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.

E. Navas, S. Moreno, F. Dronda, 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Implementation of a lung cancer screening initiative in HIV-infected subjects

S. Moreno, M. Pérez-Elías, L. Gorospe, 2021, PloS one.

High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use.

E. Ruiz-Mateos, M. Leal, L. Tarancón-Díez, 2019, Virus research.

Monitoring the CD4/CD8 ratio: a promising indicator of disease progression in HIV-infected individuals?

S. Moreno, T. Sainz, S. Serrano-Villar, 2015 .

Social isolation in HIV-infected patients according to subjective patient assessment and DEXA-confirmed severity of lipodystrophy

S. Moreno, M. Pérez-Elías, J. Casado, 2013, AIDS care.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.

S. Moreno, M. Pérez-Elías, A. Antela, 2003, AIDS.

Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015

S. Moreno, J. Berenguer, R. Muga, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Severity of the Toxicity Associated With Combinations That Include Didanosine Plus Stavudine in HIV-Infected Experienced Patients

S. Moreno, M. Pérez-Elías, A. Antela, 2006, Journal of acquired immune deficiency syndromes.

Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008–2010

Gemma Navarro, B. Hernández-Novoa, S. Moreno, 2013, Antiviral therapy.

Anti-latency agents to purge HIV reservoirs

S. Moreno, 2012, Retrovirology.

A Clinical Study of the Combination of 100 mg Ritonavir plus 800 mg Indinavir as Salvage Therapy: Influence of Increased Plasma Drug Levels in the Rate of Response

S. Moreno, M. Pérez-Elías, A. Antela, 2000, HIV clinical trials.

Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients

F. Vidal, S. Moreno, X. Barber, 2017, Journal of acquired immune deficiency syndromes.

CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

Anne M Johnson, C. Morrison, P. Vanhems, 2017, The Journal of antimicrobial chemotherapy.

Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers

R. Cruz, M. López-Huertas, S. Moreno, 2021, Emerging microbes & infections.

Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.

B. Hernández-Novoa, S. Moreno, E. Bernal, 2011, Current HIV research.

[Potential role of rilpivirine in simplification regimens].

S. Moreno, J. Casado, 2013, Enfermedades infecciosas y microbiologia clinica.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions

M. Hernán, A. Winston, C. Sabin, 2017, Journal of acquired immune deficiency syndromes.

Cost of Switching Darunavir + Ritonavir ( DRV + RTV ) to Lopinavir / Ritonavir ( LPV / r ) in HIV-1-infected Treatment-naïve Women of Child-bearing Age ( WOCBA ) P 091

A. Muriel, S. Moreno, F. Dronda, 2012 .

[Occupational exposures to blood-borne pathogens in health care workers].

S. Moreno, M. Segovia, A. Menasalvas, 2001, Enfermedades infecciosas y microbiologia clinica.

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

C. Morrison, P. Vanhems, A. Kamali, 2017, HIV medicine.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade

Á. Holguín, R. Delgado, J. Galán, 2014, Archives of Virology.

Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART

S. Moreno, M. Pérez-Elías, J. Casado, 2013, HIV clinical trials.

[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].

J. Miro, J. Gatell, E. Martinez, 2002, Enfermedades Infecciosas y Microbiologia Clinica.

CD4+:CD8+ T-cell Ratio Changes in People with HIV Receiving Antiretroviral Treatment

C. Sabin, C. Quereda, J. Galán, 2020, Antiviral therapy.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

M. Hernán, D. Podzamczer, A. Winston, 2014, Neurology.

[HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)].

C. Tural, J. Miro, M. Salavert, 2009, Enfermedades Infecciosas y Microbiologia Clinica.

Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc

B. Aguado, F. Díez-Fuertes, J. Alcamí, 2018, Journal of Virology.

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

D. Podzamczer, J. Macías, S. Moreno, 2021, Open forum infectious diseases.

New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144

J. Blanco, M. Leal, I. Rosado-Sánchez, 2020, Scientific Reports.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

T. Chun, A. Somasunderam, E. Sinclair, 2016, PLoS pathogens.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

A. Somasunderam, E. Sinclair, D. Asmuth, 2016, PLoS pathogens.

Strategies for the cure of HIV infection.

S. Moreno, S. Moreno, Jesús Rodríguez-Muñoz, 2019, Enfermedades infecciosas y microbiologia clinica.

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, The Journal of infection.

Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1–Infected Patients Treated With Combined Antiretroviral Therapy

E. Siles, F. Vidal, J. Blanco, 2015, Journal of Acquired Immune Deficiency Syndromes.

Early diagnosis.

S. Moreno, J. Berenguer, Santiago Moreno, 2018, Enfermedades infecciosas y microbiologia clinica.

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

M. Bleda, S. Moreno, F. Pulido, 2010, BMC infectious diseases.

[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].

B. Clotet, J. Miro, J. Gatell, 2004 .

Efavirenz in HIV infection.

S. Moreno, Casado Jl, 2000, The New England journal of medicine.

Interplay between gut microbiota metabolism and inflammation in HIV infection

M. Ferrer, C. Barbas, A. Latorre, 2018, The ISME Journal.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).

D. Podzamczer, E. Negredo, J. Miro, 2019, Enfermedades infecciosas y microbiologia clinica.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

S. Moreno, R. Sánchez-de la Rosa, Luis Herrera, 2008, Clinical therapeutics.

Limitations of a Simplification Antiretroviral Strategy for HIV-Infected Patients with Decreasing Adherence to a Protease Inhibitor Regimen

S. Moreno, M. Pérez-Elías, A. Antela, 2006, HIV clinical trials.